CoChat

Glucagon‐like peptide‐1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials

Cheng, Liang, Hu, Yun, Li, Yun‐Yun, Cao, Xin, Bai, Ning, Lu, Ting‐Ting, Li, Guo‐Qing, Li, Na, Wang, An‐Ning, Mao, Xiao‐Ming · 2019 · Diabetes/Metabolism Research and Reviews
Cited by 111

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and the risk of bone fracture in patients with type 2 diabetes mellitus (T2DM). Materials and methods: We conducted a systematic literature search in PubMed, Embase, the Cochrane Library, and Web of Science from inception to 28 February 2018 and identified eligible randomized controlled trials. The following data were extracted from each study: first author, year of publication, sample size, patient characteristics, study design, intervention drug, control drug, follow‐up time, and incident bone fracture events. A meta‐analysis was conducted using Review Manager 5.3 software to calculate the odds ratio (OR) and 95% confidence intervals (CI) for dichotomous variables. Results: A total of 38 studies with 39 795 patients with T2DM were included. There were 241 incident bone fracture cases (107 in the GLP‐1 RAs group and 134 in the control group). Compared with patients who received placebo and other anti‐diabetic drugs, those who received GLP‐1 RAs treatment showed a pooled OR of 0.71 (95% CI, 0.56‐0.91) for bone fracture. Subgroup analysis showed that treatments with liraglutide and lixisenatide were associated with significantly reduced risk of bone fractures (ORs, 0.56; 95% CI, 0.38‐0.81 and 0.55; 95% CI, 0.31‐0.97, respectively). However, other GLP‐1 RAs did not show superiority to placebo or other anti‐diabetic drugs. Moreover, these beneficial effects were dependent on the duration of GLP‐1 RAs treatment, only a GLP‐1 RAs treatment period of more than 52 weeks could significantly lower the risk of bone fracture in patients with T2DM (OR, 0.71; 95% CI, 0.56‐0.91). Conclusions: Compared with placebo and other anti‐diabetic drugs, liraglutide and lixisenatide were associated with a significant reduction in the risk of bone fractures, and the beneficial effects were dependent on the duration of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.3168

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 22

  1. 10.1016/j.lpm.2013.02.313 · DOI
  2. 10.18632/oncotarget.23937 · doi:10.18632/oncotarget.23937
  3. 10.1002/jbmr.3435 · DOI
  4. 10.2147/TCRM.S131945 · DOI · Paper page
  5. 10.1007/s11914-015-0265-0 · DOI
  6. 10.1016/j.cca.2006.03.017 · DOI
  7. 10.3389/fendo.2018.00006 · DOI · Paper page
  8. 10.1007/s00198-017-4096-y · DOI
  9. 10.1016/j.ecl.2013.06.005 · DOI
  10. 10.1146/annurev-physiol-021113-170315 · DOI · Paper page
  11. 10.1007/s40618-014-0137-y · DOI
  12. 10.3389/fendo.2017.00098 · DOI · Paper page
  13. GentilellaR PechtnerV CorcosA ConsoliA.Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?2018;35(1):e3070.https://doi.org/10.1002/dmrr.3070 · DOI · Paper page
  14. 10.1016/j.jdiacomp.2018.04.005 · DOI
  15. 10.1016/j.diabres.2016.03.009 · DOI · Paper page
  16. 10.1007/s00198-017-4021-4 · DOI
  17. 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  18. 10.1111/1753-0407.12372 · DOI
  19. 10.1007/s00774-018-0960-x · DOI
  20. Dubey A, 2000, The effects of diabetes on outcome after hip fracture, Bull Hosp Jt Dis, 59, 94
  21. 10.1155/2012/519784 · DOI
  22. 10.1016/j.stemcr.2016.02.002 · DOI · Paper page

Cited by

Metadata

Authors
Cheng, L., Hu, Y., Li, Y., Cao, X., Bai, N., Lu, T., Li, G., Li, N., Wang, A., & Mao, X.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2019-05-06
Volume
35
Issue
7
Pages
e3168-e3168
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2937718630
Cited by
111
References
8
FWCI
4.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.